Getting the adrenaline going: crystal structure of the adrenaline-synthesizing enzyme PNMT.
Martin, J.L., Begun, J., McLeish, M.J., Caine, J.M., Grunewald, G.L.(2001) Structure 9: 977-985
- PubMed: 11591352 
- DOI: https://doi.org/10.1016/s0969-2126(01)00662-1
- Primary Citation of Related Structures:  
1HNN - PubMed Abstract: 
Adrenaline is localized to specific regions of the central nervous system (CNS), but its role therein is unclear because of a lack of suitable pharmacologic agents. Ideally, a chemical is required that crosses the blood-brain barrier, potently inhibits the adrenaline-synthesizing enzyme PNMT, and does not affect other catecholamine processes. Currently available PNMT inhibitors do not meet these criteria. We aim to produce potent, selective, and CNS-active PNMT inhibitors by structure-based design methods. The first step is the structure determination of PNMT.
Organizational Affiliation: 
Centre for Drug Design and Development and Special Research Centre for Functional and Applied Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia. j.martin@imb.uq.edu.au